An Inhaler Diary That Writes Itself
During an asthma review, a clinician may ask how often a patient has needed a reliever inhaler during the past month. The answer usually relies on memory, which can be unreliable when symptoms vary from week to week. A missed maintenance dose can be equally hard to reconstruct. Electronic inhaler attachments offer an alternative: they record when a device is actuated and make the pattern visible afterward.
Polish company FindAir received US FDA 510(k) clearance for FindAir ONE for pressurized metered-dose inhalers (pMDIs) on June 2, 2026, and announced it publicly later that month. The compact accessory sits on top of a compatible inhaler canister. Its practical promise is a better record of inhaler use for people with asthma or chronic obstructive pulmonary disease (COPD), particularly when a clinician is trying to understand why control remains poor.
What FindAir ONE Actually Detects
Each press of the inhaler canister activates the accessory’s mechanical sensor. FindAir ONE stores the time and occurrence of the actuation, then transfers the log over Bluetooth to a compatible mobile device using FindAir Viewer. If a connection is unavailable, the FDA documentation says the accessory can hold up to 127 usage records; older events are overwritten when that capacity is exceeded.
The attachment is intended for a single user and can be moved to a replacement compatible inhaler. FDA documents specify canister diameters of 20.5–23.5 mm, with at least 7 mm of the canister protruding above the inhaler housing. That level of detail matters more at the pharmacy counter than a sweeping claim of universal compatibility. A patient should confirm the particular inhaler model before assuming the add-on will fit. The sensor records an actuation. It does not directly measure how much medication reached the lungs. Nor does it verify that the patient shook an inhaler when required, formed an adequate mouth seal, inhaled at the correct speed or held their breath afterward. Those steps affect drug delivery, but a button press cannot reveal all of them. The device’s FDA-cleared intended use concerns documenting pMDI use, and the accessory is not intended to diagnose or treat disease.
The Difference between Taking a Dose and Taking It Well
Incorrect inhaler technique is common even among experienced patients. A 2025 systematic review in npj Primary Care Respiratory Medicine found persistent technique-related errors after education across studies involving asthma and COPD. For pMDIs, poor coordination between pressing and breathing can cause medication to deposit in the mouth rather than reach the airways. Skipping a prescribed maintenance dose presents a different problem: the drug is never administered at all. These failures demand different interventions. A usage log can reveal long gaps between recorded maintenance doses or frequent reliever actuations. It cannot show whether every recorded inhalation was effective. If symptoms continue despite apparently regular use, observing the patient’s technique remains essential. Inhaler selection, spacer use and training must still be addressed in person or through appropriate clinical support.
The 2026 Global Initiative for Asthma (GINA) strategy continues to place emphasis on checking inhaler technique and medication adherence before assuming that prescribed treatment has failed. Digital monitoring may make the adherence part of that assessment less speculative. It should make the clinical conversation more specific, not replace it with a percentage on a dashboard.
Can Electronic Monitoring Prevent Exacerbations?
Evidence for connected inhaler programs is encouraging, though it does not belong entirely to FindAir. A systematic review and meta-analysis published in 2026 examined 28 randomized trials involving 4,410 participants. When electronic monitoring was combined with feedback, inhaler adherence improved by an average of about 18 percentage points compared with standard care. Some measures of asthma control and exacerbation frequency also improved, although confidence in the exacerbation evidence was lower.
A Dutch cluster-randomized trial published in 2025 gives a useful counterweight. In the ACCEPTANCE trial, adults with suboptimally controlled asthma used monitored inhalers; the intervention group also received app-based information and reminders. Adherence improved early, but the difference between groups was no longer statistically significant at the end of the year. Asthma control remained better in the intervention group. Digital reminders can have an initial effect that fades, so the surrounding care program matters.
Neither study establishes that FindAir ONE by itself prevents attacks. Many trials tested devices with alerts, coaching or clinical feedback, and their populations and medication types differed. Counting events is the beginning of a monitoring intervention. Clinical benefit depends on whether a patient or care team recognizes a pattern and responds appropriately.
What the Clinician Can Learn From a Month of Data
Consider two patients with frequent asthma symptoms. One has large gaps in recorded use of a daily controller inhaler. The other records nearly all scheduled doses but still needs a reliever repeatedly. The first pattern raises questions about forgotten treatment, cost, a complicated regimen or concerns about side effects. The second points toward checking inhaler technique, diagnosis, triggers and the suitability of the treatment plan.
Reliever use has its own meaning. A cluster of recorded actuations may coincide with a respiratory infection or environmental exposure. It can also flag deteriorating control that deserves timely review.
The event log alone cannot distinguish a genuine dose from accidental pressing or tell whether symptoms improved afterward. Using the information well requires medication context and an agreement about who will review it.
The FDA filing describes the FindAir Viewer application as showing the data collected from the accessory. Notably, the filing says the app itself does not include direct sharing with clinicians in the way the predicate Ochsner system did. FindAir describes broader remote therapeutic monitoring services, but integrations and clinical workflows need to be distinguished from what the cleared app specifically provides. Patients should not assume that their physician is automatically watching incoming data.
Compatibility, Access and Data Responsibility
The FindAir attachment uses a non-rechargeable battery, avoiding another daily charging task. That is a practical advantage for users who already manage several medicines and devices. Still, the sensor must be attached correctly, paired with a compatible phone and transferred when the inhaler canister changes. It will not work on every dry-powder inhaler merely because FindAir makes add-ons for other inhaler families.
FDA clearance allows marketing under the cleared conditions; it does not establish an ordinary retail price, universal insurance reimbursement or immediate availability from every US pharmacy. FindAir has emphasized partnerships with remote monitoring providers. Patients may encounter the technology through a care program rather than by purchasing an accessory directly. The costs of hardware, software support and clinician review should be considered separately when judging affordability.
Medication-use data also deserve privacy safeguards. A timestamped log can reveal periods away from home, sleep routines or changes in a person’s health. A patient should know where the records are stored, who can access them and what happens when they stop using a monitoring service. More granular data are helpful only if the person understands the arrangement.
A Smaller, More Realistic Role for the Smart Inhaler
For a patient who often forgets maintenance medication, an objective record may uncover a solvable problem. For a clinician weighing a higher drug dose, it can help separate irregular use from apparent lack of effect. For someone with COPD and several inhalers, it may add useful context, although the clinical evidence should be evaluated for that specific population rather than borrowed wholesale from asthma trials.
FindAir ONE does a narrow job: it remembers inhaler actuations. That job has value because human memory is imperfect and prescriptions do not document what actually happened at home. The improvement in care, however, comes when those records support a conversation about symptoms, correct technique and treatment. A smarter inhaler cannot compensate for an inappropriate prescription or an ineffective breath.
References
- U.S. Food and Drug Administration. (2026, June 2). FindAir ONE for pMDI: 510(k) clearance and summary (K260270). https://www.accessdata.fda.gov/cdrh_docs/pdf26/K260270.pdf
- FindAir. (2026, June 22). FindAir secures FDA clearance to launch smart inhaler add-ons in the US market. https://www.findair.eu/resources/news/findair-secures-fda-clearance-to-launch-smart-inhaler-add-ons-in-the-us-market/
- Global Initiative for Asthma. (2026). Global strategy for asthma management and prevention: 2026 report. https://ginasthma.org/2026-gina-strategy-report/
- Marko, M., & Pawliczak, R. (2025). Inhalation technique-related errors after education among asthma and COPD patients using different types of inhalers: Systematic review and meta-analysis. npj Primary Care Respiratory Medicine, 35, Article 15. https://doi.org/10.1038/s41533-025-00422-0
- Chen, X., Xu, L., Yang, C., Wu, X., Feng, M., & Wu, Y. (2026). Feedback-enhanced electronic monitoring for asthma inhaler adherence: A systematic review and meta-analysis of randomized controlled trials. International Journal of Nursing Studies, 184, 105675. https://doi.org/10.1016/j.ijnurstu.2026.105675
- van de Hei, S. J., van den Berg, L. N., Poot, C. C., Gerritsma, Y. H., Meijer, E., Flokstra-de Blok, B. M. J., Postma, M. J., van Boven, J. F. M., Chavannes, N. H., & Kocks, J. W. H. (2025). Long-term effectiveness of a digital inhaler on medication adherence and clinical outcomes in adult asthma patients in primary care: The cluster randomized controlled ACCEPTANCE trial. The Journal of Allergy and Clinical Immunology: In Practice, 13(7), 1693–1704. https://doi.org/10.1016/j.jaip.2025.03.013